Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07168785 · ClinicalTrials.gov registry record · Early Phase 1
[18F]-AraG PET Imaging in LA HNSCC
A Early Phase 1 study, sponsored by Indiana University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT07168785: Clinical Trial Early Phase 1 study, sponsored by Indiana University.
NCT07168785 is a Early Phase 1 study that has not yet begun recruiting, run by Indiana University. The registered enrollment target is 5 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07168785, a Early Phase 1 study, has not yet begun recruiting, sponsored by Indiana University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study will use \[18F\]-AraG PET/CT scans to monitor patients who have been diagnosed with locally advanced Head and Neck Squamous Cell carcinoma (LA-HNSCC), and are planning to undergo standard of care chemoradiotherapy for treatment.
Primary Outcome
Examining the distribution of \[18F\]-AraG PET SUV metrics and counts of CD3+/CD8+/PD1- and CD3+/CD8+/PD1+ T-cells
Interventions
- DRUG Chemotherapy
- DEVICE Radiotherapy
- DRUG [18F]-AraG radiotracer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2027-10 |
| Phase | Early Phase 1 |
What is known before NCT07168785 opens enrollment
NCT07168785 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which Chemotherapy is the first listed.
NCT07168785 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07168785 about?
NCT07168785 is a clinical study titled "[18F]-AraG PET Imaging in LA HNSCC". This study will use \[18F\]-AraG PET/CT scans to monitor patients who have been diagnosed with locally advanced Head and Neck Squamous Cell carcinoma (LA-HNSCC), and are planning to undergo standard of care chemoradiotherapy for treatment.
What is the current status of trial NCT07168785?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2025-10-01. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07168785?
The interventions under investigation include: Chemotherapy (DRUG), Radiotherapy (DEVICE), [18F]-AraG radiotracer (DRUG).
Who is sponsoring clinical trial NCT07168785?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07168785's enrollment target sits among peer trials
5 1887th of 2000 higher than 80 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI